Eli Lilly (NYSE:LLY) shares rose on Wednesday after the FDA approved Foundayo, a new oral weight-loss drug, strengthening the company’s position in the obesity market.
In the ATTAIN-1 trial, adults on the highest dose lost an average of 27 pounds, or 12.4% of body weight. The once-daily pill will be available via LillyDirect at $25 per month for commercially insured patients and $149 for self-pay.
Foundayo marks Lilly’s second FDA-approved obesity treatment, with plans to expand into more than 40 countries following the U.S. launch.
Lilly said eligible Medicare Part D patients could access the drug for $50 per month starting July 2026. The company also noted it should not be used alongside other GLP-1 receptor agonists.
The approval comes as broader markets rise, with the S&P 500 up 1.2% and healthcare stocks gaining 1.16%. Lilly shares outperformed the sector, signaling strong investor response to the launch.
Technical Analysis
The stock is currently trading 1.3% above its 20-day simple moving average (SMA) and 5.4% below its 100-day …
This post was originally published here
